Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Plain-language summary

This study is examining a cascade genetic screening approach - testing relatives as well - in families with hereditary breast and ovarian cancer syndrome. Patients with ovarian, fallopian tube or primary peritoneal cancer carrying a known pathogenic mutation, along with their untested first- or second-degree relatives, are eligible. The study had no assigned phase and is being carried out; it is currently not recruiting but is ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

NYU Langone Health

Intervention

CASCADE genetic screening

Start date

3/1/2019

Estimated completion

4/23/2027

Countries

United States

Related genes

Locations

• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All subjects must have a diagnosis of epithelial ovarian cancer, Fallopian tube caner or primary peritoneal cancer with a known pathogenic genetic mutation.
* All subjects must agree to participate.
* All subjects must have first or second degree relatives who have not been diagnosed with the same genetic mutation.
* A previous diagnosis of cancer in the subject's first or second degree relative is allowed.

Exclusion Criteria:

* Subjects whose first and/or second degree relatives have already been tested with the subject's known mutations, and no other viable family members are available for testing.